Vanguard Capital Management
IBRX icon

Vanguard Capital Management’s ImmunityBio IBRX Stock Holding History

Vanguard Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$137M Buy
15,691,579
+563,865
+4% +$4.27M ﹤0.01% 1373
2026
Q1 		$116M Buy
+15,127,714
New +$104M ﹤0.01% 1390

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Capital Management's IBRX Position: Q2 2026 in Review

Vanguard Capital Management increased its ImmunityBio (IBRX) stake by 3.7% in Q2 2026, buying an estimated $4.27M and bringing the position to 15,691,579 shares worth $137M. The position accounts for ﹤0.01% of the portfolio, ranked #1373.

Vanguard Capital Management first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 402 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Vanguard Capital Management held 15,691,579 shares of ImmunityBio worth $137M as of Q2 2026.
  • Vanguard Capital Management bought 563,865 ImmunityBio shares in Q2 2026, an estimated $4.27M.
  • ImmunityBio made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1373 holding.
  • Vanguard Capital Management first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • 402 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.